Literature DB >> 32530454

Convalescent Plasma and COVID-19.

Anurag N Malani1, John P Sherbeck1, Preeti N Malani2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32530454     DOI： 10.1001/jama.2020.10699

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Stratifying Deterioration Risk by Acuity at Admission Offers Triage Insights for Coronavirus Disease 2019 Patients.

Authors:  Joseph Beals; Jaime J Barnes; Daniel J Durand; Joan M Rimar; Thomas J Donohue; S Mahfuz Hoq; Kathy W Belk; Alpesh N Amin; Michael J Rothman
Journal:  Crit Care Explor       Date:  2021-04-05

2.  Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.

Authors:  Henry T Peng; Shawn G Rhind; Andrew Beckett
Journal:  JMIR Public Health Surveill       Date:  2021-04-07

Review 3.  Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.

Authors:  Nandeeta Samad; Temitayo Eniola Sodunke; Hasan Al Banna; Ashmita Sapkota; Aneeka Nawar Fatema; Katia Iskandar; Dilshad Jahan; Timothy Craig Hardcastle; Tanzina Nusrat; Tajkera Sultana Chowdhury; Mainul Haque
Journal:  Risk Manag Healthc Policy       Date:  2020-11-23

Review 4.  Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.

Authors:  Pooya Farhangnia; Shiva Dehrouyeh; Amir Reza Safdarian; Soheila Vasheghani Farahani; Melika Gorgani; Nima Rezaei; Mahzad Akbarpour; Ali-Akbar Delbandi
Journal:  Int Immunopharmacol       Date:  2022-04-21       Impact factor: 5.714

Review 5.  The Immune Response to SARS-CoV-2 and Variants of Concern.

Authors:  Elham Torbati; Kurt L Krause; James E Ussher
Journal:  Viruses       Date:  2021-09-23       Impact factor: 5.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.